Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1019387-69-9 | MDL No. : | MFCD11131977 |
Formula : | C10H14N2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ZJWDUXSEAHEJED-UHFFFAOYSA-N |
M.W : | 194.23 | Pubchem ID : | 28399982 |
Synonyms : |
|
Num. heavy atoms : | 14 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.4 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 54.96 |
TPSA : | 62.22 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.29 cm/s |
Log Po/w (iLOGP) : | 1.73 |
Log Po/w (XLOGP3) : | 1.68 |
Log Po/w (WLOGP) : | 1.8 |
Log Po/w (MLOGP) : | 0.0 |
Log Po/w (SILICOS-IT) : | 1.1 |
Consensus Log Po/w : | 1.26 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.85 |
Log S (ESOL) : | -2.22 |
Solubility : | 1.17 mg/ml ; 0.006 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.6 |
Solubility : | 0.487 mg/ml ; 0.00251 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -2.66 |
Solubility : | 0.421 mg/ml ; 0.00217 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.81 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312+P330-P302+P352+P312-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P362-P363-P403+P233-P405-P501 | UN#: | N/A |
Hazard Statements: | H302+H312+H332-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.166667h; | 5.5.1 Example 5.1 (General Route) N-[(3S)-1-[6-(tert-Butylamino)pyridine-3-carbonyl]pyrrolidin-3-yl]-N-methylacetamideN-[(3S)-1-[6-(tert-Butylamino)pyridine-3-carbonyl]pyrrolidin-3-yl]-N-methylacetamide To a mixture of 2.20 g (11.4 mmol) 6-(tert-Butylamino)pyridine-3-carboxylic acid (example I), 2.43 g (13.6 mmol) N-Methyl-N-[(3S)-pyrrolidin-3-yl]acetamide hydrochloride (example VI) and 7.85 mL (45.4 mmol) DIPEA in 20 mL DMF are added 3.83 g (11.9 mmol) TBTU and the reaction mixture is stirred at RT for 10 min. The solvent is partially removed in vacuo and the remaining mixture is purified by HPLC (ACN/H2O/NH4OH). (0450) C17H26N4O2 (M=318.4 g/mol) (0451) ESI-MS: 319 [M+H]+ (0452) Rt (HPLC): 0.64 min (method B) |